Galapagos is a biotechnology company focused on the discovery and development of small molecule medicines with novel modes of action. The company is dedicated to improving the lives of patients by targeting diseases with high unmet medical needs. With a strong emphasis on research and development, it has built a robust pipeline of drug candidates across various therapeutic areas, including inflammation, fibrosis, and kidney disease.

In terms of sustainability, Galapagos is committed to integrating environmental, social, and governance (ESG) considerations into its business operations. The company strives to minimize its environmental impact through energy-efficient practices and waste reduction initiatives. However, specific details on carbon footprint calculations or sustainability certifications are not extensively documented in public resources.

Galapagos values transparency and ethical conduct, ensuring that its operations align with high standards of corporate governance. The company actively engages with stakeholders to foster a culture of responsibility and accountability. While there is limited publicly available information on detailed sustainability metrics, Galapagos continues to work towards enhancing its sustainability practices.